Article
The role of CYP2B6 516G>T polymorphism on efavirenz/nevirapine toxicity. Implications on treatment outcomes: Lessons from Botswana.
Medicine - 29 Apr 2022
Maseng Monkgomotsi J, Tawe Leabaneng, Thami Prisca K, Moyo Sikhulile, Kasvosve Ishmael, Novitsky Vladimir, Essex Max, Russo Gianluca, Gaseitsiwe Simani, Paganotti Giacomo M
Abstract excerpt
ABSTRACT: The two non-nucleoside reverse transcriptase inhibitors (NNRTIs), efavirenz (EFV) and nevirapine (NVP), are currently the core antiretroviral drugs for treatment of HIV in sub-Saharan Africa including Botswana. The drugs are metabolized by Cytochrome P450 2B6 (CYP2B6) liver enzyme. The CYP2B6 gene that encodes for metabolism of these drugs is known to be highly polymorphic. One of the polymorphism in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
